Akeso Biopharma has successfully raised approximately $250 million through a share placement, drawing significant recognition from international investment firms. The placement saw a majority of subscribers from long-term and healthcare-focused funds, highlighting Akeso’s strong appeal in the global investment landscape. This substantial capital influx serves as a testament to Akeso’s impressive track record in drug […]
Summit Therapeutics Inc. has announced a significant milestone in its oncology development efforts, completing patient enrollment for the HARMONi Phase III clinical trial. This pivotal study seeks to evaluate the efficacy of Ivonescimab, a novel bispecific antibody, in combination with platinum-doublet chemotherapy as a second-line treatment for patients with epidermal growth factor receptor-mutated (EGFRm) non-squamous […]
